Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency

被引：16
|
作者：
Badros, A. Z.
Vij, R.
Martin, T.
Zonder, J. A.
Wong, A. F.
Woo, T.
Boussina, K.
Wang, Z.
Niesvizky, R.
机构：
[1] Univ Maryland, Baltimore, MD 21201 USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[5] Onyx Pharmaceut, Emeryville, CA USA
[6] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.8128
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8128
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PHASE II STUDY OF CARFILZOMIB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND VARYING DEGREES OF RENAL INSUFFICIENCY
    Niesvizky, R.
    Vij, R.
    Martin, T.
    Zonder, J.
    Boussina, K.
    Wang, Z.
    Woo, T.
    Wong, A.
    Badros, A.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 159 - 159
  • [2] Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma
    Lendvai, Nikoletta
    Landau, Heather
    Lesokhin, Alexander
    Tsakos, Ioanna
    Koehne, Guenther
    Chung, David
    Devlin, Sean
    Hassoun, Hani
    Giralt, Sergio A.
    [J]. BLOOD, 2012, 120 (21)
  • [3] Phase I Study of Carfilzomib in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (MM) and Varying Degrees of Renal Insufficiency
    Badros, Ashraf Z.
    Vij, Ravi
    Martin, Thomas
    Zonder, Jeffrey A.
    Woo, Tina
    Wang, Zhengping
    Lee, Susan
    Wong, Alvin
    Niesvizky, Ruben
    [J]. BLOOD, 2009, 114 (22) : 1492 - 1492
  • [4] Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
    Berdeja, Jesus G.
    Hart, Lowell L.
    Mace, Joseph R.
    Arrowsmith, Edward R.
    Essell, James H.
    Owera, Rami S.
    Hainsworth, John D.
    Flinn, Ian W.
    [J]. HAEMATOLOGICA, 2015, 100 (05) : 670 - 676
  • [5] Phase II Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (PX-171-003)
    Jagannath, S.
    Vij, R.
    Stewart, A. K.
    Somlo, G.
    Jakubowiak, A.
    Reiman, T.
    Trudel, S.
    Taylor, J.
    Fuhrman, D.
    Cruickshank, S.
    Schwartz, R.
    Kunkel, L.
    Siegel, D.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S61 - S61
  • [6] A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
    Watanabe, Takashi
    Tobinai, Kensei
    Matsumoto, Morio
    Suzuki, Kenshi
    Sunami, Kazutaka
    Ishida, Tadao
    Ando, Kiyoshi
    Chou, Takaaki
    Ozaki, Shuji
    Taniwaki, Masafumi
    Uike, Naokuni
    Shibayama, Hirohiko
    Hatake, Kiyohiko
    Izutsu, Koji
    Ishikawa, Takayuki
    Shumiya, Yoshihisa
    Kashihara, Tomohisa
    Iida, Shinsuke
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (05) : 745 - 756
  • [7] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hans C. Lee
    Jatin J. Shah
    Lei Feng
    Elisabet E. Manasanch
    Rebecca Lu
    Ashley Morphey
    Brandon Crumpton
    Krina K. Patel
    Michael L. Wang
    Raymond Alexanian
    Sheeba K. Thomas
    Donna M. Weber
    Robert Z. Orlowski
    [J]. Blood Cancer Journal, 9
  • [8] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Shah, Jatin J.
    Feng, Lei
    Manasanch, Elisabet E.
    Lu, Rebecca
    Morphey, Ashley
    Crumpton, Brandon
    Patel, Krina K.
    Wang, Michael L.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Weber, Donna M.
    Orlowski, Robert Z.
    [J]. BLOOD CANCER JOURNAL, 2019, 9 (10)
  • [9] A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for Relapsed or Refractory Multiple Myeloma
    Fiala, Mark A.
    Keller, Jesse
    Sekhar, Jeevan
    Ceriotti, Connie
    Abboud, Camille N.
    DiPersio, John F.
    Tomasson, Michael H.
    Wildes, Tanya M.
    Stockerl-Goldstein, Keith
    Vij, Ravi
    [J]. BLOOD, 2016, 128 (22)
  • [10] phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Sperling, Adam
    Bianchi, Giada
    Munshi, Nikhil
    O'Donnell, Elizabeth
    Branagan, Andrew
    Avigan, David
    Liegel, Jessica
    Harrington, Cynthia
    Agyemang, Emerentia
    Lively, Kathleen
    Packer, Lisette
    Han, Samuel
    Minsky, Cole
    Riadi, Manal
    Mcvey, Cailin
    Donnelly, Kaleigh
    Smith, Caitlin
    Katzeff, Mackenna
    Goguen, Amy
    Horick, Nora
    Richardson, Paul
    Raje, Noopur
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S220 - S221
12345